vilaprisan vilaprisan vilaprisan (inn, usan) (developmental code name bay-1002670) is a synthetic and steroidal selective progesterone receptor modulator (sprm) which is under development by bayer healthcare pharmaceuticals for the treatment of endometriosis and uterine fibroids. it is a potent and highly selective partial agonist of the progesterone receptor (pr). as of 2017, the drug is in phase ii clinical trials for the aforementioned indications. vilaprisanclinical dataother namesbay-1002670; 17β-hydroxy-11β--17α-(1,1,2,2,2-pentafluoroethyl)estra-4,9-dien-3-oneroutes ofadministrationby mouthdrug classselective progesterone receptor modulatoridentifiers iupac name (8s,11r,13s,14s,17s)-17-hydroxy-13-methyl-11-(4-methylsulfonylphenyl)-17-(1,1,2,2,2-pentafluoroethyl)-1,2,6,7,8,11,12,14,15,16-decahydrocyclopentaphenanthren-3-one cas number1262108-14-4pubchem cid50915138chemspider32699892uniiin59k53gi9keggd11181chemical and physical dataformulac27h29f5o4smolar mass544.58 g·mol−13d model (jsmol)interactive image smiles c12c(c3=c4ccc(=o)c=c4cc31cc2(c(c(f)(f)f)(f)f)o)c5=cc=c(c=c5)s(=o)(=o)c inchi inchi=1s/c27h29f5o4s/c1-24-14-21(15-3-7-18(8-4-15)37(2,35)36)23-19-10-6-17(33)13-16(19)5-9-20(23)22(24)11-12-25(24,34)26(28,29)27(30,31)32/h3-4,7-8,13,20-22,34h,5-6,9-12,14h2,1-2h3/t20-,21+,22-,24-,25-/m0/s1key:jufwqqvhqfduod-anrpbidpsa-n